Stockreport

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licens [Read more]